9338 results for "cancer rna-seq"

in 30.85 milliseconds.

• CAGE analysis for endometrial carcinoma

  For endometrial cancer patients, lymphadenectomy is recommended to exclude rarely metastasized cancer cells. This procedure is performed even in patients with low risk of recurrence despite the risk of complications such as lymphedema. A method to accurately identify cases with no lymph node metastases (LN-) before lymphadenectomy is therefore highly required. We approached this clinical problem by examining primary lesions of endometrial cancers with CAGE (Cap Analysis Gene Expression), which quantifies promoter-level expression across the genome. Fourteen profiles delineated distinct transcriptional networks between LN?+?and LN- cases, within those classified as having the low or intermediate risk of recurrence.

  Study JGAS000124

• Primary breast cancers and paired brain metastases sequencing study

  Improving management of brain metastases (BM) from primary breast cancer (PBC) is a challenge in which targeted therapies play a promising role. However this approach is impaired by miss-knowledge of molecular patterns of the metastatic and drug-resistance processes.We performed a differential analysis of copy-number-alterations (CNAs) and mutations profiles by using pan-genomic array-CGH and targeted next-generation-sequencing of 494 cancer-associated genes, in a series of 14 pairs of matched PBC/BM and assessed if the observed genomic alterations may be used as a druggable agent in a clinical trial.

  Study EGAS00001003173

• ICGC Prostate Cancer Whole Genome Sequencing

  To characterize the subclonal genomic architecture of androgen-deprived metastatic prostate cancer, we performed whole-genome sequencing (WGS) of 51 tumours from 10 patients to an average sequencing depth of 55x, including multiple metastases from different anatomic sites in each patient and, in five cases, the prostate tumour. Noncancerous DNA from blood or other tissue is used as reference comparison for each patient. The patients are part of PELICAN (Project to ELIminate Lethal Cancer) rapid autopsy study led by G. Steven Bova at Johns Hopkins University (USA) and Tampere University (Finland). As of September 2020, some of the studies using these data include: Gundem et al, Nature 2015 (PMID: 25830880). Additional EGAD00001000891 sample metadata is contained in Supplementary Information in this report.Tubio et al, Science 2014 (PMID: 25082706) Behjati et al, Nature Comm 2015 (PMID: 27615322) Wedge et al, Nature Genetics 2018 (PMID: 29662167)Pan-Cancer Analysis of Whole Genomes, Nature 2020 (PMID: 32025007)Rodriguez-Martin et al, Nature Genetics 2020 (PMID: 32024998)Woodcock et al, Nature Comm 2020 (In Press)

  Dataset EGAD00001000891

• UCL Cancer Institute DAC

  Dac EGAC00001001579

• DAC of Synergie Lyon Cancer

  Dac EGAC00001000382

• Data Access Committee for COLO829 Somatic reference standard for cancer genome sequencing

  Dac EGAC00001000408

• DAC for study Treg in breast cancer and healthy individuals

  Dac EGAC00001000638

• DAC for NKTL study. National Cancer Centre Singapore.

  Dac EGAC00001000640

• Stanford Data Access Committee for Breast Cancer Tumor Heterogeneity through Treatment

  Dac EGAC00001000993

• Genome-wide association study of cervical cancer in East Asian populations

  Dac EGAC00001001024

• University Clinic Erlangen/ German Cancer Research Center rare tumors data access committee

  Dac EGAC00001001053

• Stanford Data Access Committee for Multi-Region WES of Metastatic Colorectal Cancer

  Dac EGAC00001001164

• NKI (Netherlands Cancer Institute)

  Dac EGAC00001001648

• Division of Molecular Oncology, National Cancer Center Research Institute Data Access Committee

  Dac EGAC00001002331

• University of Melbourne Centre for Cancer Research (UMCCR) Data Access Committee

  Dac EGAC00001002442

• Netherlands Cancer Institute (NKI) - Wilbert Zwart Group

  Dac EGAC00001003257

• The Landscape of N-6 Methyladenosine in Primary Localized Prostate Cancer

  Study EGAS00001006925

• Elucidating the molecular landscape of KRAS/BRAF mutant colorectal cancers

  Study EGAS00001007459

• Recurrent somatic DICER1 mutations in non-epithelial ovarian tumors

  Study EGAS00001000135

• Integrated genetic analysis of primary CNS lymphoma

  Study EGAS00001007222

• Characterization of alternative promoter usage in advanced prostate cancer

  Study EGAS00001006275

• Molecular characterization of a renal cell carcinoma PDX cohort

  Study EGAS00001006249

• GBM stem cell lines and PRMT5 inhibitor

  Study EGAS00001004397

• AUBTRG - Whole Exome Sequencing of Diffuse Glioma Samples

  Study EGAS00001003035

• Study of the microenvironment of angioimmunoblastic T-cell lymphoma

  Study EGAS00001006401